Caspase‐3: A primary target for natural and synthetic compounds for cancer therapy
Caspases, a group of protease enzymes (cysteine proteases), exist as inactive zymogens in
the cells and execute apoptosis (programmed cell death). Caspase‐3, an executioner …
the cells and execute apoptosis (programmed cell death). Caspase‐3, an executioner …
Ligand-based design on the dog-bone-shaped BIBR1532 pharmacophoric features and synthesis of novel analogues as promising telomerase inhibitors with in vitro …
Telomerase is an outstanding biological target for cancer treatment. BIBR1532 is a non-
nucleoside selective telomerase inhibitor; however, it experiences ineligible …
nucleoside selective telomerase inhibitor; however, it experiences ineligible …
Caspase-3 activators as anticancer agents
N Srivastava, AK Saxena - Current Protein and Peptide Science, 2023 - ingentaconnect.com
Background: The cancer is still a major cause of death worldwide. Among different targets to
design anticancer agents, caspase-3 is an important target as its cleavage and activation …
design anticancer agents, caspase-3 is an important target as its cleavage and activation …
Discovery of new pyrimidine-5-carbonitrile derivatives as anticancer agents targeting EGFR WT and EGFR T790M
A new series of pyrimidine-5-carbonitrile derivatives has been designed as ATP mimicking
tyrosine kinase inhibitors of the epidermal growth factor receptor (EGFR). These compounds …
tyrosine kinase inhibitors of the epidermal growth factor receptor (EGFR). These compounds …
New quinoxaline-based VEGFR-2 inhibitors: Design, synthesis, and antiproliferative evaluation with in silico docking, ADMET, toxicity, and DFT studies
A new series of 3-methylquinoxaline-based derivatives having the same essential
pharmacophoric features as VEGFR-2 inhibitors have been synthesized and evaluated for …
pharmacophoric features as VEGFR-2 inhibitors have been synthesized and evaluated for …
New quinoxaline derivatives as VEGFR-2 inhibitors with anticancer and apoptotic activity: Design, molecular modeling, and synthesis
Abstract New series of [1, 2, 4] triazolo [4, 3-a] quinoxalin-4 (5H)-one and [1, 2, 4] triazolo [4,
3-a] quinoxaline derivatives have been designed, synthesized, and biologically assessed for …
3-a] quinoxaline derivatives have been designed, synthesized, and biologically assessed for …
New bis ([1, 2, 4] triazolo)[4, 3-a: 3′, 4′-c] quinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers: Design, synthesis, in silico studies, and anticancer …
A new series of bis ([1, 2, 4] triazolo)[4, 3-a: 3′, 4′-c] quinoxaline derivatives were
designed and synthesized to have the main essential pharmacophoric features of VEGFR-2 …
designed and synthesized to have the main essential pharmacophoric features of VEGFR-2 …
Design, synthesis, and biological evaluation of new challenging thalidomide analogs as potential anticancer immunomodulatory agents
Thalidomide and its analogs are immunomodulatory drugs that inhibit the production of
certain inflammatory mediators associated with cancer. In the present work, a new series of …
certain inflammatory mediators associated with cancer. In the present work, a new series of …
Design, molecular docking, in vitro, and in vivo studies of new quinazolin-4 (3H)-ones as VEGFR-2 inhibitors with potential activity against hepatocellular carcinoma
A series of new VEGFR-2 inhibitors were designed, synthesized and evaluated for their anti-
proliferative activities against hepatocellular carcinoma (HepG-2 cell line). Compound 29 b …
proliferative activities against hepatocellular carcinoma (HepG-2 cell line). Compound 29 b …
Development of isatin-thiazolo [3, 2-a] benzimidazole hybrids as novel CDK2 inhibitors with potent in vitro apoptotic anti-proliferative activity: Synthesis, biological and …
In the current medical era, human health is experiencing numerous challenges, particularly
the human malignancies. Therefore, the therapeutic arsenal for these malignancies is to be …
the human malignancies. Therefore, the therapeutic arsenal for these malignancies is to be …